Until recently, all pharmacology characterization was involving in vitro and in vivo studies. Important efforts arebeing made to refine in vitro and animal models to ensure better translation to human physiology in health and disease. Today, drug discovery faces however rising numbers of new molecules to evaluate vs. increasing costs of drug discovery and results not always meeting expectations. This raises the need of novel analytical tools to complete data collected in vitro and in vivo: this became possible with the development of computational sciences.
The aim of this whitepaper is to look and advantages and limits of toxicology predicition in regards to the current regulatory environment.
Download the full whitepaper now
Fill in the form to download the content
whitepaper by
Carlo Chiavaroli, PhD
Senior Director, Nonclinical & Early Clinical Development
As Director, Nonclinical, and Early Clinical Development, Carlo is responsible for leading projects for which strategic considerations are particularly challenging.…
View profile
Cécile F. Rousseau, PhD
Senior Director, Nonclinical
With 10+ years in nonclinical and translational research and histotechnology, Dr. Cécile F. Rousseau has considerable expertise in medical devices,…
View profile
All our resources 
